Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

To assess the cost-effectiveness of blood pressure (BP)-lowering and cholesterol-lowering drugs for cardiovascular disease (CVD) prevention.We constructed a Markov model in which the Thai population was classified by 10-year absolute CVD risk and modeled the use of BP- and cholesterol-lowering drugs, including a "polypill" (three BP-lowering drugs and a statin). We applied "do-nothing" as the comparator, a health sector perspective on lifetime cost-effectiveness, 3% discounting of costs and effects, and used probabilistic sensitivity analysis. Outcomes are expressed as average and incremental cost-effectiveness in Thai baht per disability-adjusted life-year averted.The polypill would be a very cost-effective option for CVD prevention even in people at modest risk (10-year risk of 5%-9.9%). Use of the three most cost-effective BP drugs is also associated with a net cost saving and large health gain at risk levels greater than 5%. Adding a generic statin gives a price per disability-adjusted life-year of 0.5 (10-year risk at 20%+) to 1.5 (10-year risk at 5%-9.9%) times Thai per-capita gross domestic product using lowest available annual costs. However, at current average drug prices, adding a statin would be considered cost-effective only for those with a 10-year absolute CVD risk of 20% and more.Primary CVD prevention with the polypill or a combination of three generic BP-lowering drugs is very cost-effective in the Thai population.

Original publication

DOI

10.1016/j.vhri.2012.03.019

Type

Journal article

Journal

Value in health regional issues

Publication Date

25/05/2012

Volume

1

Pages

15 - 22

Addresses

The Setting Priorities using Information on Cost-Effectiveness Project, Ministry of Public Health, Mueang, Nontaburi, Thailand; The Department of Pharmacy, Maharat Nakhonratchasima Hospital, Mueang, Nakhonratchasima, Thailand; The University of Queensland, School of Population Health, Brisbane, Australia. Electronic address: panarasik@yahoo.com.